Gerresheimer Shares Face Critical Deadline Amid Regulatory Scrutiny

German pharma packaging firm Gerresheimer under intense BaFin investigation, plans major asset write-downs and divestitures, with financial forecasts sharply downgraded.

The Düsseldorf-based pharmaceutical packaging specialist Gerresheimer is navigating a perfect storm of regulatory challenges, delayed financial reports, and substantial asset write-downs. With Germany's financial watchdog, BaFin, expanding its investigation and casting doubt on several balance sheet items, the company faces a firm deadline of March 31 to file its audited annual report—failure to do so risks escalating its troubles significantly.

Strategic Divestitures and Closures Underway

In response to the mounting pressure, Gerresheimer's management has initiated strategic countermeasures. The company plans to sell its U.S. subsidiary Centor, a manufacturer of high-margin packaging systems for prescription drugs, by 2026, with Morgan Stanley advising on the transaction. Conversely, a previously planned sale of the Moulded Glass business has been halted. Instead, the Chicago plant will be shuttered by the end of this year.

Regulatory Probe Intensifies with New Findings

BaFin's examination has uncovered specific indications that the financial statements for 2023/24 contain further errors. Consequently, the regulator is extending its scrutiny to include the half-year report for 2024/25. While the initial focus was on so-called bill-and-hold contracts, where revenue was allegedly booked prematurely, the probe now also encompasses leasing liabilities worth €65.5 million and capitalized development costs of €29.4 million, which may have been reported incorrectly.

A particularly serious allegation from the authority suggests that impairment charges for the Swiss subsidiary Sensile Medical and the U.S. unit Moulded Glass Chicago should have been recognized in earlier financial years. Gerresheimer is currently planning write-downs between €220 and €240 million, but BaFin suspects these losses were foreseeable in prior periods.

Internal Investigation Complicates Reporting Timeline

Prompted by internal tips, Gerresheimer has engaged a second auditing firm alongside its regular auditor. The company alleges that certain employees violated internal guidelines and accounting rules. The necessary corrections primarily affect revenue recognition and the accounting and valuation of inventory.

This internal turmoil has disrupted the reporting calendar. The annual results, originally scheduled for release on February 26, have been postponed. The audited annual and group financial statements are now expected by March 31, followed by the quarterly report on April 16.

Financial Forecasts Downgraded Sharply

The accounting issues are having a direct and severe impact on key financial metrics. The adjusted EBITDA margin is now projected to be 16.5% to 17.5%, a significant reduction from the previous guidance of 18.5% to 19.0%. Adjusted earnings per share are anticipated to fall by a high double-digit percentage, with a net loss now a distinct possibility. Management had previously forecast only a mid double-digit decline.

For the current fiscal year, the company maintains its revenue target of €2.3 to €2.4 billion.

Share Price Plummets to Decade Low

Investor confidence has eroded dramatically. In late February, Gerresheimer's stock hit €15.51, its lowest level in over ten years. The share price has fallen approximately 80% from its 52-week high of €82, recorded in March 2025. Since the start of the year, the decline exceeds 37%.

Despite the profound uncertainty, some investors are showing interest. On March 3, the CastleKnight Master Fund LP disclosed a 4.08% stake. Deka Investment has also published a voting rights notification. Meanwhile, the Deutsche Schutzvereinigung für Wertpapierbesitz (DSW), a German shareholder association, is examining potential claims for damages and has encouraged affected investors to come forward. The company's CEO and CFO have already been replaced.

The March 31 deadline will serve as a crucial test for the new leadership's ability to clean up the accounts transparently. Should they fail, the stock is likely to revisit its recent lows.